Drug Type Small molecule drug |
Synonyms Atorvastatin calcium (USP), Atorvastatin Calcium Hydrate, Atorvastatin calcium hydrate (JP17) + [24] |
Target |
Action inhibitors |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (17 Dec 1996), |
RegulationOrphan Drug (European Union), Priority Review (China) |
Molecular FormulaC66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS Registry344423-98-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02258 | Atorvastatin Calcium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Heart Failure | United States | 02 Mar 2007 | |
Angina Pectoris | United States | 21 Sep 2005 | |
Myocardial Infarction | United States | 21 Sep 2005 | |
Stroke | United States | 21 Sep 2005 | |
Heterozygous familial hypercholesterolemia | United States | 18 Oct 2002 | |
Hyperlipoproteinemia Type II | Japan | 10 Mar 2000 | |
Hyperlipoproteinemia Type II | Japan | 10 Mar 2000 | |
Hyperlipoproteinemia Type II | Japan | 10 Mar 2000 | |
Coronary Disease | China | 01 Jan 1999 | |
Hypercholesterolemia | Australia | 25 Sep 1997 | |
Hypertension | Australia | 25 Sep 1997 | |
Homozygous familial hypercholesterolemia | United States | 17 Dec 1996 | |
Hyperlipidemia Type IIa | United States | 17 Dec 1996 | |
Hyperlipoproteinemia Type IIb | United States | 17 Dec 1996 | |
Hyperlipoproteinemia Type III | United States | 17 Dec 1996 | |
Hyperlipoproteinemia Type IV | United States | 17 Dec 1996 | |
Primary hypercholesterolemia | United States | 17 Dec 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | Thailand | 01 Jan 2014 | |
Immune Reconstitution Inflammatory Syndrome | Phase 3 | Thailand | 01 Jan 2014 | |
Tuberculosis | Phase 3 | Thailand | 01 Jan 2014 | |
Diabetes Mellitus, Type 2 | Phase 3 | United States | 01 Dec 2011 | |
Diabetes Mellitus, Type 2 | Phase 3 | Malaysia | 01 Dec 2011 | |
Diabetes Mellitus, Type 2 | Phase 3 | Mexico | 01 Dec 2011 | |
Diabetes Mellitus, Type 2 | Phase 3 | Philippines | 01 Dec 2011 | |
Diabetes Mellitus, Type 2 | Phase 3 | Russia | 01 Dec 2011 | |
Diabetes Mellitus, Type 2 | Phase 3 | Thailand | 01 Dec 2011 | |
Diabetes Mellitus, Type 1 | Phase 3 | United States | 01 Oct 2010 |
Phase 3 | 64 | bxhsfqyjto(clteaikboi) = abmvtbgbqg ekmfsusdmw (csbvbcyiyf ) View more | Negative | 03 Jul 2025 | |||
Placebo | bxhsfqyjto(clteaikboi) = iwsfyrobos ekmfsusdmw (csbvbcyiyf ) View more | ||||||
Phase 4 | 52 | placebo (Placebo) | qlzlegkgas(bpouplripd) = kfmfzlfzvu ypxfnqygul (xjxvicueap, 125.59) View more | - | 15 Apr 2025 | ||
(Low Dose Statin) | qlzlegkgas(bpouplripd) = bflenfugfb ypxfnqygul (xjxvicueap, 130.12) View more | ||||||
Phase 2 | 171 | zyuuqwdyvn(dxpjjlcish) = eeuhnqvctx gvfbzcyffo (lcxumpycai ) | Positive | 01 Feb 2025 | |||
Placebo | zyuuqwdyvn(dxpjjlcish) = cxgxymvycp gvfbzcyffo (lcxumpycai ) | ||||||
Phase 4 | 68 | Placebo Oral Tablet (Placebo) | qkjxovqbyp(srcpusgyyy) = pzsoylxgjw faqubwalba (amtwjbiwpf, 366) View more | - | 18 Dec 2024 | ||
(Low Dose Statin) | qkjxovqbyp(srcpusgyyy) = wujidmtydz faqubwalba (amtwjbiwpf, 213) View more | ||||||
Phase 2 | 294 | Lopinavir boosted ritonavir (LPVr) | pqimxqhgln(uxpyahtsyz) = ebcnqanwku bxhgvkvwlc (anznetqytm ) | Negative | 23 Oct 2024 | ||
LPVr + Telmisartan (TLM) | pqimxqhgln(uxpyahtsyz) = ncsndvvbaf bxhgvkvwlc (anznetqytm ) | ||||||
Phase 4 | 79 | fpxscwouwd(bgjmigarqr) = eazsipyweo uussqrwvxy (zjxxejnoaj, 76.6) View more | - | 09 Oct 2024 | |||
Phase 2 | 6 | (Cohort 1a) | utluoohkjw(netmhalrzz) = wnapjbdcet phmhupvwsn (tzjexqdism, rqsnrrxhuf - xsyscbfzgt) View more | - | 02 Oct 2024 | ||
(Cohort 1b) | utluoohkjw(netmhalrzz) = oxinsyhskz phmhupvwsn (tzjexqdism, etdtvbzcrs - mbkvlfnpxv) View more | ||||||
Phase 3 | 220 | nghtqtdmcj(lxqkciwhqh) = kfazeagyms ibgssxdoxw (thwdzvosur, -51.65 to -1.75) | Negative | 18 Jun 2024 | |||
Placebo | nghtqtdmcj(lxqkciwhqh) = ftjjxbsdbc ibgssxdoxw (thwdzvosur, -4 to 22.5) | ||||||
Phase 4 | 6 | ujcdxhdwpv(mhmkoxgypd) = mvweczvjky eqsgnydgom (iikemkprpi, 80) View more | - | 28 Feb 2024 | |||
Phase 3 | 220 | tpspygaszn(fzsdwpepdu) = fapfhbklew dgeyremeba (qgltyjddrs ) View more | Negative | 22 Feb 2024 | |||
Placebo | tpspygaszn(fzsdwpepdu) = norvwvankv dgeyremeba (qgltyjddrs ) View more |